<DOC>
	<DOCNO>NCT03096418</DOCNO>
	<brief_summary>The hypothesis study paclitaxel level increase chromosomal instability ( CIN ) tumor lethal tumor pre-existing CIN . Treatment administer outpatient basis . Paclitaxel initiated standard infusion day 1 , 8 , 15 1-day cycle . Participants continue paclitaxel cycle 2-4 prior surgery .</brief_summary>
	<brief_title>Neoadjuvant Weekly Paclitaxel Biomarkers Therapy Response</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Women pathologically demonstrate breast cancer Patients must candidate neoadjuvant paclitaxel chemotherapy treat oncologist Patients must metastatic disease stag workup chest imaging , CBC , liver function study . A formalinfixed paraffin embed tumor block ( prefer ) unstained slide must available prior biopsy primary tumor . A minimum 8 slide must available . The primary tumor must readily biopsied surgery radiology team . The primary tumor must measurable image modality prior treatment . This imaging modality repeat completion 4 cycle paclitaxel prior surgery . Such imaging modality may include ultrasound , CT , mammography , MRI . MRI prefer image modality available high accuracy positive predictive value predict pathologic complete response.All imaging perform per standard care discretion treat physician . Subjects may prior systemic chemotherapy target therapy regimen administer treatment current breast cancer . Patients must adequate organ marrow function determine treat oncologist . Patient must willing undergo additional biopsy breast tumor . Patient must ability willingness sign write informed consent document . Women childbearing potential must agree use effective contraception discuss treat oncologist duration study . Patients systemic chemotherapy , target therapy radiotherapy cancer within 5 year prior enter study . History allergic reaction attribute compound similar chemical biologic composition paclitaxel include drug formulate Cremophor ( R ) EL ( polyoxyethylated castor oil ) . Patients know HIV due concern chemotherapy may cause immunosuppression potential infectious complication . Patients nonaspirin anticoagulation ( Coumadin , heparins , clopidogrel ) document bleed disorder exclude due risk bleed biopsy . Uncontrolled intercurrent illness include , limited , ongoing active severe infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , malignancy require therapy psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study paclitaxel pregnancy category D drug may cause deleterious effect fetus . Because unknown potential risk adverse event nurse infant secondary treatment mother paclitaxel , breastfeed discontinue mother enrol trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>